2-Tert-butyl-4-(5-chloro-2-methoxy-4-phenylbenzoyl)piperazine-1-carboxylic acid

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-Tert-butyl-4-(5-chloro-2-methoxy-4-phenylbenzoyl)piperazine-1-carboxylic acid
• 英文别名: 2-tert-butyl-4-(5-chloro-2-methoxy-4-phenylbenzoyl)piperazine-1-carboxylic acid
• 化学式: C₂₃H₂₇ClN₂O₄
• 分子量: 430.9
• InChiKey: NJDZTZACBDEYEC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.7
• 重原子数：
  30
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.39
• 拓扑面积：
  70.1
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• COVALENT INHIBITORS OF KRAS G12C
  申请人：Araxes Pharma LLC

  公开号：EP2970121A1

  公开（公告）日：2016-01-20
• COMBINATION THERAPIES FOR TREATMENT OF CANCER
  申请人：Araxes Pharma LLC

  公开号：US20190262342A1

  公开（公告）日：2019-08-29

  Combination therapies for treatment of cancers associated with mutations in the KRAS gene are provided. Compositions comprising therapeutic agents for treatment of cancers associated with mutations in the KRAS gene are also provided.
• [EN] COVALENT INHIBITORS OF KRAS G12C<br/>[FR] INHIBITEURS COVALENTS DE K-RAS G12C
  申请人：ARAXES PHARMA LLC

  公开号：WO2014152588A1

  公开（公告）日：2014-09-25

  Irreversible inhibitors of G12C mutant K-Ras protein are provided. Also disclosed are methods to modulate the activity of G12C mutant K-Ras protein and methods of treatment of disorders mediated by G12C mutant K-Ras protein.